beta-(氨基甲基)-4-甲基-苯丙酸盐酸盐 | 28311-38-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: beta-(氨基甲基)-4-甲基-苯丙酸盐酸盐
• 英文名称: 4-amino-3-(p-tolyl)butanoic acid
• 英文别名: 3-p-Tolyl-4-amino-buttersaeure (rac.)；4-azaniumyl-3-(4-methylphenyl)butanoate
• CAS: 28311-38-8
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: MSZRPURXKHMSFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为产物：
  描述：

  4-甲苯硼酸 在 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 sodium tetrahydroborate 、 四丁基氯化铵 、 水 、 溶剂黄146 、 cesium fluoride 、 三氟乙酸 、 nickel dichloride 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 、 水 、 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 38.0h， 生成 beta-(氨基甲基)-4-甲基-苯丙酸盐酸盐
  参考文献：
  名称：

  β-Substituted γ-butyrolactams from mucochloric acid: synthesis of (±)-baclofen and other γ-aminobutyric acids and useful building blocks

  摘要：

  已开发出一种方法，使用简单和温和的条件，从黏氯酸开始，选择性地在β位取代生成γ-丁内酰胺。该方法进一步扩展到合成(±)-巴氯芬和其他γ-氨基丁酸。

  DOI：

  10.1039/c3ra42201a

文献信息

• SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF
  申请人：Bayer Aktiengesellschaft

  公开号：US20200031775A1

  公开（公告）日：2020-01-30

  The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.

  本申请涉及新型取代N-芳基乙基-2-芳基喹啉-4-羧酰胺衍生物，其制备方法，其单独或组合用于治疗和/或预防疾病的用途，以及其用于生产治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防纤维化和炎症性疾病。
• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF BACLOFEN AND ITS INTERMEDIATE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE BACLOFÈNE ET DE SON INTERMÉDIAIRE
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2017009753A1

  公开（公告）日：2017-01-19

  The present invention provides an improved process for the preparation of 3-(4-chlorophenyl)-3- cyanopropanoic acid (compound (A)) and further its transformation to Baclofen (I). The process comprises reaction of compound (II) with Glyoxylic acid to obtain 3-(4-chlorophenyl)-3- cyanoacrylic acid (III); followed by the 'in- situ' reduction of (III) in the presence of a reducing agent to provide the compound (A). Alternatively, the compound (A) is obtained by the process comprising reacting 2-(4- chlorophenyl)acetonitrile (II) with haloacetic acid (IV) in the presence of a base. The compound 3-(4-chlorophenyl)-3-cyanopropanoic acid (A) undergoes hydrogenation in the presence of a metal catalyst and ammonia solution to provide Baclofen (I).

  本发明提供了一种改进的方法，用于制备3-(4-氯苯基)-3-氰丙酸（化合物A）以及进一步将其转化为巴氯芬（I）。该方法包括将化合物（II）与乙醛酸反应，以获得3-(4-氯苯基)-3-氰丙烯酸（III）；随后，在还原剂存在下对（III）进行“原位”还原以提供化合物（A）。另外，通过在碱存在下将2-(4-氯苯基)乙腈（II）与卤代乙酸（IV）反应的方法也可以得到化合物（A）。化合物3-(4-氯苯基)-3-氰丙酸（A）在金属催化剂和氨溶液存在下发生氢化反应，从而得到巴氯芬（I）。
• Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
  申请人：Bayer Aktiengesellschaft

  公开号：US11136296B2

  公开（公告）日：2021-10-05

  The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.

  本申请涉及新型取代的 N-芳基乙基-2-芳基喹啉-4-甲酰胺衍生物、其制备工艺、其单独使用或组合使用以治疗和/或预防疾病，以及其用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防纤维化和炎症性疾病。
• BACLOFEN FOR USE IN THE TOPICAL TREATMENT OF LOCALIZED MUSCULOSKELETAL PAIN
  申请人：ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

  公开号：US20220008372A1

  公开（公告）日：2022-01-13

  Methods of administering compounds of Baclofen and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, are provided for topical treatment and prevention of localized musculoskeletal pain.
• [EN] METHOD FOR TREATMENT OF ACQUIRED COGNITIVE DEFICITS<br/>[FR] PROCÉDÉ DE TRAITEMENT DE DÉFICIENCES COGNITIVES ACQUISES
  申请人：UNIV CORNELL

  公开号：WO2021154767A1

  公开（公告）日：2021-08-05

  The present disclosure is directed to methods for improving a wakeful function in a subject suffering from an acquired cognitive deficiency by administering to the subject an effective amount of an upregulator of GABAB signaling, thereby improving the wakeful function in the subject. Another aspect of the disclosure us directed to methods for improving a wakeful function in a subject suffering from an acquired cognitive deficiency by administering to the subject an effective amount of an upregulator of GABAB signaling at night, in combination with administering an anterior-forebrain stimulating therapy when the subject is awake, thereby improving the wakeful function in the subject.